Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020 Post published:September 21, 2023 Post category:Press Release
Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments Post published:December 15, 2022 Post category:Press Release
Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022 Post published:March 24, 2022 Post category:Press Release